"In 2006, Health Canada approved the first vaccine to prevent Human
Papillomavirus (HPV) infection (Gardasil, Merck Frosst Canada Ltd).
GardasilÂ® is a highly effective quadrivalent HPV vaccine targeting highrisk HPV subtypes 16 and 18 as well as low-risk HPV subtypes 6 and 11 . The National Advisory Committee on Immunization (NACI)
released a statement in 2007 with the recommendation to vaccinate
girls between 9 and 13 years of age for the prevention of infection
caused by the HPV subtypes 6, 11, 16, and 18 and their associated
diseases like cervical cancer, vulvar and vaginal cancers, genital warts
(Condyloma Acuminata, Cervical Adenocarcinoma In Situ (AIS),
Cervical Intraepithelial Neoplasia (CIN) grades 1, 2 and 3, vulvar and
Vaginal Intraepithelial Neoplasia (VIN) grades 2 and 3. In February
2010, GardasilÂ® was authorized to expand its indications to include
males 9 to 26 years of age for the prevention of infection caused by
HPV subtypes 6, 11, 16, and 18. In April 2011, GardasilÂ® was approved
for use in women up to the age of 45 years.
Since then, HPV vaccination programs have become widespread in
Canada. On May of 2008, Manitoba has announced the introduction
of a HPV immunization program whereby every grade six girl will be
vaccinated with Gardasil, provided consent from her parent or legal
guardian is obtained . (Wadi KAl, Poliquin V, Poliquin G, Lotocki R, Avery L (2014) The Perceived Role of Physicians with Regard to the Human Papillomavirus Vaccine.)"
Last date updated on November, 2020